Sutro Biopharma, Inc. (STRO )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol STRO
- Company Sutro Biopharma, Inc.
- Price $11.01
- Changes Percentage -17.09
- Change -2.27
- Day Low $10.84
- Day High $13.19
- Year High $43.85
- Year Low $7.15
- Market Cap $152,029,692
- Price Avg 50 EMA (D) $21.28
- Price Avg 200 EMA (D) $22.74
- Exchange NASDAQ
- Volume 250,385
- Average Volume 356,349
- Open $13.11
- Previous Close $13.28
- EPS -17.26
- PE -0.91
- Earnings Announcement 2026-11-05 05:00:00
- Shares Outstanding $9,677,256
Company brief: SUTRO BIOPHARMA, INC. (STRO )
- Healthcare
- Biotechnology
- Mr. William J. Newell J.D.
- https://www.sutrobio.com
- US
- N/A
- 09-27-2018
- US8693671021
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.